Compare HTHT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTHT | BMRN |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.0B |
| IPO Year | 2010 | 1999 |
| Metric | HTHT | BMRN |
|---|---|---|
| Price | $50.26 | $57.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $47.00 | ★ $90.15 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 11-17-2025 | 02-18-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | 7.24 | ★ 59.53 |
| EPS | 1.76 | ★ 2.68 |
| Revenue | ★ $3,484,239,807.00 | $3,094,001,000.00 |
| Revenue This Year | $7.12 | $13.42 |
| Revenue Next Year | $6.64 | $10.81 |
| P/E Ratio | $28.49 | ★ $21.33 |
| Revenue Growth | 5.77 | ★ 12.39 |
| 52 Week Low | $30.20 | $50.76 |
| 52 Week High | $51.46 | $73.51 |
| Indicator | HTHT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 50.15 |
| Support Level | $48.02 | $54.07 |
| Resistance Level | $51.46 | $61.88 |
| Average True Range (ATR) | 1.42 | 1.63 |
| MACD | -0.10 | -0.42 |
| Stochastic Oscillator | 69.70 | 37.33 |
H World Group Ltd is a multi-brand hotel group in China with international operations. It operates in the leased, managed, and franchised models. The company has two operating segments: legacy Huazhu and legacy DH. Its brand and product offering includes Economy hotel brands: HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, and Ibis Hotel, Midscale hotel brands: JI Hotel, Orange Hotel, Starway Hotel and Ibis Styles Hotel, Upper midscale hotel brands: Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, CitiGO Hotel and MAXX by Steigenberger, Upscale hotel brands: Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, Jaz in the City, and Grand Mercure; and Luxury hotel brand: Steigenberger Icon and Song Hotels.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.